Price: (as of – Details) Specifications: Net Content:50g Weight:160g For People: Universal Applicable Skin Type: Universal Package Included: 1/ Pcs Package Dimensions : […]
Virtual care company’s commitment to providing high-quality, delightful healthcare experiences is evolving workplace well-being.
CHICAGO, July 20, 2023 (Newswire.com)
–
First Stop Health (FSH), a leading virtual care company for primary, urgent and mental health care needs, is proud to announce its recognition as a winner of the esteemed 2023 Well-Being Trailblazer Award. Presented by Archetype and the Wellness Council of America (WELCOA), this prestigious award celebrates FSH’s contributions to the well-being industry and its commitment to transforming workplace wellness.
“When we provide new services, we do so for the betterment of our users – employees and their family members across the country. That desire is what drove our decision to launch Virtual Primary Care in 2022,” said FSH CEO, Teira Gunlock. “We are excited to be considered a Trailblazer for our approach in delivering convenient, compassionate care.”
“These remarkable companies are leading the way in transforming the well-being landscape, and we have full confidence that they will continue to drive positive change in the sphere of workplace well-being,” commented Iain Fitzpatrick, Chief Strategy Officer at Archetype. “Their innovative approaches and unwavering commitment to improving employee well-being are shaping the future of the industry.”
Presented by Archetype and the Wellness Council of America (WELCOA), the Well-Being Trailblazer Awards celebrate innovative companies reshaping workplace wellness. These prestigious awards recognize organizations enhancing employee well-being, promoting resilience, and setting new standards for well-being technology, products, and services.
FSH is proud to provide care that people love® and its +94 Virtual Primary Care Net Promoter Score (NPS) reflects its commitment to members’ well-being. FSH virtual care is designed to promote equitable, culturally competent and quality-assured healthcare to support the unique needs of patients.
About First Stop Health
First Stop Health (FSH) provides care that people love with various digital healthcare services. Patients can access virtual care 24/7 via app, website or phone. We help them save time and money with safe, convenient, high-quality virtual care solutions – Primary Care, Urgent Care & Mental Health. FSH was named one of Inc. Magazine’s Best Workplaces of 2022 and 2023, and ranked one of the fastest-growing private companies for the past five years by Inc. 5000. FSH was also recognized in Crain’s Chicago Business Fast 50 and ranked one of the Chicago area’s fastest-growing companies.
Contact Information:
Emily Kunisch
Senior Manager, Marketing
888-691-7867 x-410
Original Source:
First Stop Health Honored as Winner of the 2023 Well-Being Trailblazer Award
The post First Stop Health Honored as Winner of the 2023 Well-Being Trailblazer Award first appeared on Enrose Magazine.
The post First Stop Health Honored as Winner of the 2023 Well-Being Trailblazer Award appeared first on IGP Beauty.
Price: (as of – Details) From the Publisher Publisher : Skyhorse (August 15, 2023) Language : English Hardcover : […]
Take a look back at the last 100 years of plastic surgery, from dangerous paraffin injections in the 1920s and board-certified plastic surgeons in the […]
Price: (as of – Details) From the brand QINSEN Workout Dress Series 2023 MUST HAVE Tennis Dress COLLECTION QINSEN is a professional online retailer for […]
Price: (as of – Details) Staying hydrated is the new flex. This serum is designed to draw + hold moisture in the skin thanks to […]
Price: (as of – Details) Water, Cyclopentasiloxane, Isododecane, Trimethylsiloxysilicate, Butylene Glycol, Triethoxycaprylylsilane, Cetyl PEG/PPG-10/1 Dimethicone, VP/Eicosene Copolymer, Cyclohexasiloxane, Propylene Carbonate, Quaternium-90 Bentonite, Caprylyl Methicone, Polypropylsilsesquioxane, […]
Laser Hair Removal at Home, Permanent Hair Removal || IPL Laser Treatment The handset i used is from Erikka IPL – https://bit.ly/3yu5EyV As you all […]
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease
NAPA, Calif., July 19, 2023 (Newswire.com)
–
Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages of Alzheimer’s Disease.
Neurovations began enrolling patients in 2021 in advance of Eli Lilly’s recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer’s Disease.
“We are thrilled to be part of this vital research. Alzheimer’s Disease affects nearly 1 million people in my home state of California,” said Dr. Eric Grigsby. “This is a significant step forward in the fight against Alzheimer’s, and we are optimistic about the impact this treatment may have on the members of my community with this condition.”
Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research for pain and neurologic diseases, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience.
The TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, evaluated the safety and efficacy of donanemab, an investigational, amyloid-targeting therapy. Participants with early symptomatic Alzheimer’s disease were enrolled in the study, and those with confirmed presence of AD neuropathology completed their course of treatment with donanemab.
Neurovations Research was selected as a study site in 2021 and worked with Eli Lilly to contribute to this groundbreaking research. Dr. Grigsby’s expertise and passion for advancing treatments for neurodegenerative diseases and chronic pain have been instrumental in the success of this collaboration.
Key findings from the TRAILBLAZER-ALZ 2 study include:
● Nearly half (47%) of participants on donanemab showed no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to 29% of participants on placebo.
● Donanemab treatment slowed clinical decline by 35% compared to placebo, leading to a 40% reduction in the decline of activities of daily living.
These results have significant implications for the treatment of early symptomatic Alzheimer’s disease and have prompted Lilly to move forward with FDA approval and global regulatory submissions. Neurovations and Dr. Eric Grigsby’s involvement in this study have further enhanced the research community’s understanding of the potential benefits of donanemab in Alzheimer’s disease management.
“Alzheimer’s Disease affects an estimated 6.7 million Americans aged 65 and older. This first step is monumental on the path to a cure. We are thrilled to have been part of the study and sincerely hope to begin offering the treatment as soon as possible,” stated Dr Grigsby.
Contact Information:
Krista Clark
Marketing Director
7072529665
Original Source:
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
The post Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease appeared first on AESTHETIC NEWS.
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer’s Disease
NAPA, Calif., July 19, 2023 (Newswire.com)
–
Neurovations, a leading medical research and innovation company, is proud to have collaborated on a groundbreaking study investigating the effects of the monoclonal antibody, donanemab, on patients with the early stages of Alzheimer’s Disease.
Neurovations began enrolling patients in 2021 in advance of Eli Lilly’s recent announcement of positive results from the TRAILBLAZER-ALZ 2 Phase 3 trial. This study demonstrated that donanemab significantly slowed cognitive and functional decline in individuals with early Alzheimer’s Disease.
“We are thrilled to be part of this vital research. Alzheimer’s Disease affects nearly 1 million people in my home state of California,” said Dr. Eric Grigsby. “This is a significant step forward in the fight against Alzheimer’s, and we are optimistic about the impact this treatment may have on the members of my community with this condition.”
Neurovations was founded in Napa in 1992 by Dr. Eric Grigsby and is a national leader in clinical research for pain and neurologic diseases, treatment for chronic pain, molecular diagnostics testing, and education programs focused on pain and neuroscience.
The TRAILBLAZER-ALZ 2 study, a randomized, double-blind, placebo-controlled trial, evaluated the safety and efficacy of donanemab, an investigational, amyloid-targeting therapy. Participants with early symptomatic Alzheimer’s disease were enrolled in the study, and those with confirmed presence of AD neuropathology completed their course of treatment with donanemab.
Neurovations Research was selected as a study site in 2021 and worked with Eli Lilly to contribute to this groundbreaking research. Dr. Grigsby’s expertise and passion for advancing treatments for neurodegenerative diseases and chronic pain have been instrumental in the success of this collaboration.
Key findings from the TRAILBLAZER-ALZ 2 study include:
● Nearly half (47%) of participants on donanemab showed no clinical progression at one year, defined as no decline in Clinical Dementia Rating-Sum of Boxes (CDR-SB), compared to 29% of participants on placebo.
● Donanemab treatment slowed clinical decline by 35% compared to placebo, leading to a 40% reduction in the decline of activities of daily living.
These results have significant implications for the treatment of early symptomatic Alzheimer’s disease and have prompted Lilly to move forward with FDA approval and global regulatory submissions. Neurovations and Dr. Eric Grigsby’s involvement in this study have further enhanced the research community’s understanding of the potential benefits of donanemab in Alzheimer’s disease management.
“Alzheimer’s Disease affects an estimated 6.7 million Americans aged 65 and older. This first step is monumental on the path to a cure. We are thrilled to have been part of the study and sincerely hope to begin offering the treatment as soon as possible,” stated Dr Grigsby.
Contact Information:
Krista Clark
Marketing Director
7072529665
Original Source:
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
The post Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease appeared first on AESTHETIC NEWS.
Copyright © 2024 | WordPress Theme by MH Themes
